---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-071261"
form_type: "8-K"
ticker: "NVCT"
cik: "0001875558"
company_name: "Nuvectis Pharma, Inc."
filed_at: "2024-06-13T23:59:59+00:00"
generated_at: "2026-06-01T04:41:55.226562+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Nuvectis Pharma stockholders re-elect directors and ratify auditor at 2024 annual meeting

## Summary
- Kenneth Hoberman elected Class II director with 8,026,155 votes for, 809,797 against.
- Matthew Kaplan elected Class II director with 8,502,724 votes for, 333,228 against.
- Ratification of Kesselman & Kesselman as auditor approved: 12,055,252 for, 31,882 against.
- Voting based on 12,227,134 shares present (66.55% of outstanding) on record date April 15, 2024.
- All proposals as described in definitive proxy statement filed April 29, 2024 were approved.

## SEC filing metadata
- accession: 0001104659-24-071261
- form_type: 8-K
- ticker: NVCT
- cik: 0001875558
- company_name: Nuvectis Pharma, Inc.
- filed_at: 2024-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/0001104659-24-071261-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1875558/000110465924071261/tm2417208d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-071261
- JSON: https://secwatch.observer/filing/0001104659-24-071261.json
- Plain text: https://secwatch.observer/filing/0001104659-24-071261.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.